ID AGRF5_HUMAN Reviewed; 1346 AA.
AC Q8IZF2; O94858; Q5TF06; Q6RGN2; Q86SP0; Q9Y3Z2;
DT 19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT 05-MAY-2009, sequence version 3.
DT 04-NOV-2026, entry version 196.
DE RecName: Full=Adhesion G protein-coupled receptor F5 {ECO:0000303|PubMed:25713288};
DE AltName: Full=G protein-coupled receptor 116;
DE Flags: Precursor;
GN Name=ADGRF5 {ECO:0000312|HGNC:HGNC:19030}; Synonyms=GPR116, KIAA0758;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX PubMed=12435584; DOI=10.1016/s0014-5793(02)03574-3;
RA Fredriksson R., Lagerstroem M.C., Hoeglund P.J., Schioeth H.B.;
RT "Novel human G protein-coupled receptors with long N-terminals containing
RT GPS domains and Ser/Thr-rich regions.";
RL FEBS Lett. 531:407-414(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-604.
RC TISSUE=Brain;
RA Bonner T.I., Nagle J.W., Kauffman D.;
RT "Complete coding sequence of GPR116.";
RL Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS MET-604
RP AND THR-856.
RC TISSUE=Brain;
RX PubMed=10048485; DOI=10.1093/dnares/5.6.355;
RA Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N.,
RA Tanaka A., Kotani H., Nomura N., Ohara O.;
RT "Prediction of the coding sequences of unidentified human genes. XII. The
RT complete sequences of 100 new cDNA clones from brain which code for large
RT proteins in vitro.";
RL DNA Res. 5:355-364(1998).
RN [4]
RP SEQUENCE REVISION.
RA Ohara O., Nagase T., Kikuno R., Ishikawa K., Suyama M.;
RL Submitted (AUG-2005) to the EMBL/GenBank/DDBJ databases.
RN [5]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE
RP [LARGE SCALE MRNA] OF 1-613 (ISOFORM 1), AND VARIANTS MET-604 AND ILE-801.
RC TISSUE=Brain, and Cervix;
RX PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA Wiemann S., Schupp I.;
RT "The full-ORF clone resource of the German cDNA consortium.";
RL BMC Genomics 8:399-399(2007).
RN [6]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=14574404; DOI=10.1038/nature02055;
RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA Rogers J., Beck S.;
RT "The DNA sequence and analysis of human chromosome 6.";
RL Nature 425:805-811(2003).
RN [7]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS MET-604
RP AND THR-856.
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [8]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 949-1062.
RX PubMed=12679517; DOI=10.1073/pnas.0230374100;
RA Vassilatis D.K., Hohmann J.G., Zeng H., Li F., Ranchalis J.E.,
RA Mortrud M.T., Brown A., Rodriguez S.S., Weller J.R., Wright A.C.,
RA Bergmann J.E., Gaitanaris G.A.;
RT "The G protein-coupled receptor repertoires of human and mouse.";
RL Proc. Natl. Acad. Sci. U.S.A. 100:4903-4908(2003).
RN [9]
RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-256 AND ASN-315.
RC TISSUE=Plasma;
RX PubMed=16335952; DOI=10.1021/pr0502065;
RA Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA Smith R.D.;
RT "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT hydrazide chemistry, and mass spectrometry.";
RL J. Proteome Res. 4:2070-2080(2005).
RN [10]
RP SUBCELLULAR LOCATION.
RX PubMed=23590306; DOI=10.1165/rcmb.2012-0439oc;
RA Bridges J.P., Ludwig M.G., Mueller M., Kinzel B., Sato A., Xu Y.,
RA Whitsett J.A., Ikegami M.;
RT "Orphan G protein-coupled receptor GPR116 regulates pulmonary surfactant
RT pool size.";
RL Am. J. Respir. Cell Mol. Biol. 49:348-357(2013).
RN [11]
RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX PubMed=23684610; DOI=10.1016/j.celrep.2013.04.019;
RA Yang M.Y., Hilton M.B., Seaman S., Haines D.C., Nagashima K., Burks C.M.,
RA Tessarollo L., Ivanova P.T., Brown H.A., Umstead T.M., Floros J.,
RA Chroneos Z.C., St Croix B.;
RT "Essential regulation of lung surfactant homeostasis by the orphan G
RT protein-coupled receptor GPR116.";
RL Cell Rep. 3:1457-1464(2013).
RN [12]
RP NOMENCLATURE.
RX PubMed=25713288; DOI=10.1124/pr.114.009647;
RA Hamann J., Aust G., Arac D., Engel F.B., Formstone C., Fredriksson R.,
RA Hall R.A., Harty B.L., Kirchhoff C., Knapp B., Krishnan A., Liebscher I.,
RA Lin H.H., Martinelli D.C., Monk K.R., Peeters M.C., Piao X., Promel S.,
RA Schoneberg T., Schwartz T.W., Singer K., Stacey M., Ushkaryov Y.A.,
RA Vallon M., Wolfrum U., Wright M.W., Xu L., Langenhan T., Schioth H.B.;
RT "International union of basic and clinical pharmacology. XCIV. Adhesion G
RT protein-coupled receptors.";
RL Pharmacol. Rev. 67:338-367(2015).
RN [13]
RP FUNCTION, IDENTIFICATION OF THE TETHERED LIGAND, AND TISSUE SPECIFICITY.
RX PubMed=28570277; DOI=10.1172/jci.insight.93700;
RA Brown K., Filuta A., Ludwig M.G., Seuwen K., Jaros J., Vidal S., Arora K.,
RA Naren A.P., Kandasamy K., Parthasarathi K., Offermanns S., Mason R.J.,
RA Miller W.E., Whitsett J.A., Bridges J.P.;
RT "Epithelial Gpr116 regulates pulmonary alveolar homeostasis via Gq/11
RT signaling.";
RL JCI Insight 2:0-0(2017).
RN [14]
RP IDENTIFICATION AS FNDC4 RECEPTOR, AND TISSUE SPECIFICITY.
RX PubMed=34016966; DOI=10.1038/s41467-021-22579-1;
RA Georgiadi A., Lopez-Salazar V., Merahbi R.E., Karikari R.A., Ma X.,
RA Mourao A., Klepac K., Buehler L., Alfaro A.J., Kaczmarek I., Linford A.,
RA Bosma M., Shilkova O., Ritvos O., Nakamura N., Hirose S., Lassi M.,
RA Teperino R., Machado J., Scheideler M., Dietrich A., Geerlof A.,
RA Feuchtinger A., Blutke A., Fischer K., Mueller T.D., Kessler K.,
RA Schoeneberg T., Thor D., Hornemann S., Kruse M., Nawroth P.,
RA Pivovarova-Ramich O., Pfeiffer A.F.H., Sattler M., Blueher M., Herzig S.;
RT "Orphan GPR116 mediates the insulin sensitizing effects of the hepatokine
RT FNDC4 in adipose tissue.";
RL Nat. Commun. 12:2999-2999(2021).
RN [15]
RP MUTAGENESIS OF 991-THR--LEU-996; GLY-1009; 1075-GLN--ASN-1077;
RP 1080-ILE--LYS-1083; ARG-1153; THR-1157; VAL-1161; 1240-PHE--THR-1243;
RP ALA-1252 AND VAL-1256.
RX PubMed=36073784; DOI=10.7554/elife.69061;
RA Bridges J.P., Safina C., Pirard B., Brown K., Filuta A., Panchanathan R.,
RA Bouhelal R., Reymann N., Patel S., Seuwen K., Miller W.E., Ludwig M.G.;
RT "Regulation of pulmonary surfactant by the adhesion GPCR GPR116/ADGRF5
RT requires a tethered agonist-mediated activation mechanism.";
RL Elife 11:0-0(2022).
CC -!- FUNCTION: Adhesion G protein-coupled receptor (PubMed:28570277). In
CC alveolar type II (ATII or AT2) cells, required for normal lung
CC surfactant homeostasis (PubMed:28570277). Modulation of both surfactant
CC secretion and uptake by ATII cells is mediated by the downstream
CC activation of GNAQ/GNA11 proteins and may be a consequence of increased
CC cortical F-actin assembly induced by ADGRF5 activation
CC (PubMed:28570277). In the kidney, may play a role in the regulation of
CC acid excretion into the primary urine, possibly by regulating the
CC surface expression of V-ATPase proton pump (By similarity). As a
CC receptor for soluble FNDC4 (sFNDC4), required for proper systemic
CC glucose tolerance, specifically sensitizing white adipose tissue to
CC insulin. Also plays a role in sFNDC4-induced decrease of local
CC inflammation in white adipose tissue (PubMed:34016966).
CC {ECO:0000250|UniProtKB:G5E8Q8, ECO:0000269|PubMed:28570277,
CC ECO:0000269|PubMed:34016966}.
CC -!- ACTIVITY REGULATION: As an adhesion G protein-coupled receptor (aGPCR)
CC exhibits a large N-terminal extracellular domain containing highly
CC conserved GPCR autoproteolysis-inducing (GAIN) domain. During
CC synthesis, intracellular autoproteolytic processing of nascent chain
CC within the GAIN domain generates a mature protein, consisting of an N-
CC terminal fragment that is non-covalently linked to the C-terminal
CC fragment. The mature protein is routed to the plasma membrane where the
CC N- and C-terminal fragments remain associated, forming the
CC holoreceptor. Dissociation of the aGPCR fragments stimulates G protein
CC signaling through the action of the tethered-peptide agonist stalk that
CC is occluded within the GAIN domain in the holoreceptor form. This
CC dissociation might be induced by ligand binding, such as that of
CC sFNDC4. {ECO:0000305}.
CC -!- SUBUNIT: Homodimer; disulfide-linked. Heterodimer of 2 chains generated
CC by proteolytic processing; the large extracellular N-terminal fragment
CC and the membrane-bound C-terminal fragment predominantly remain
CC associated and non-covalently linked. Fragment generates by the
CC processing enzyme furin remains attached to the extracellular N-
CC terminal fragment. Interacts (via N-terminal extracellular domain) with
CC SFTPD. {ECO:0000250|UniProtKB:G5E8Q8, ECO:0000250|UniProtKB:Q9WVT0}.
CC -!- INTERACTION:
CC Q8IZF2; Q9NPB3: CABP2; NbExp=3; IntAct=EBI-7600130, EBI-12011224;
CC Q8IZF2; Q53EP0-3: FNDC3B; NbExp=3; IntAct=EBI-7600130, EBI-10242151;
CC Q8IZF2; Q13952-2: NFYC; NbExp=3; IntAct=EBI-7600130, EBI-11956831;
CC Q8IZF2; P55735-3: SEC13; NbExp=3; IntAct=EBI-7600130, EBI-12235008;
CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23590306,
CC ECO:0000269|PubMed:23684610}; Multi-pass membrane protein
CC {ECO:0000255}.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=3;
CC Name=1;
CC IsoId=Q8IZF2-1; Sequence=Displayed;
CC Name=2;
CC IsoId=Q8IZF2-2; Sequence=VSP_010837, VSP_010838;
CC Name=3;
CC IsoId=Q8IZF2-3; Sequence=VSP_039130;
CC -!- TISSUE SPECIFICITY: Expressed in lung endothelial cells and in alveolar
CC type II (ATII) cells (at protein level) (PubMed:23684610,
CC PubMed:28570277). Expressed high levels in subcutaneous adipose tissue
CC in lean individuals and at lower levels in visceral fat. Expression
CC levels in subcutaneous adipose tissue drastically drop in obese
CC individuals (PubMed:34016966). {ECO:0000269|PubMed:23684610,
CC ECO:0000269|PubMed:28570277, ECO:0000269|PubMed:34016966}.
CC -!- PTM: Highly glycosylated. {ECO:0000250|UniProtKB:Q9WVT0}.
CC -!- PTM: Proteolytically cleaved at multiple sites: one in the GPS region
CC of the GAIN-B domain (S1 site) and the other in the SEA domain (S2
CC site). The proteolytic cleavage at S1 site generates an extracellular
CC subunit and a seven-transmembrane subunit. The proteolytic cleavage at
CC S2 site generates a fragment that undergoes proteolytic cleavage by the
CC processing enzyme furin. {ECO:0000250|UniProtKB:Q9WVT0}.
CC -!- SIMILARITY: Belongs to the G protein-coupled receptor 2 family.
CC Adhesion G protein-coupled receptor (ADGR) subfamily. {ECO:0000305}.
CC -!- SEQUENCE CAUTION:
CC Sequence=BAA34478.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC Sequence=CAB43394.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AY140958; AAN46672.1; -; mRNA.
DR EMBL; AY498875; AAS21061.1; -; mRNA.
DR EMBL; AB018301; BAA34478.2; ALT_INIT; mRNA.
DR EMBL; AL050295; CAB43394.1; ALT_SEQ; mRNA.
DR EMBL; AL832125; -; NOT_ANNOTATED_CDS; mRNA.
DR EMBL; AL096772; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; BC066121; AAH66121.1; -; mRNA.
DR EMBL; AY255552; AAO85064.1; -; mRNA.
DR CCDS; CCDS4919.1; -. [Q8IZF2-1]
DR PIR; T08685; T08685.
DR RefSeq; NP_001091988.1; NM_001098518.2. [Q8IZF2-1]
DR RefSeq; NP_056049.4; NM_015234.5. [Q8IZF2-1]
DR AlphaFoldDB; Q8IZF2; -.
DR SMR; Q8IZF2; -.
DR BioGRID; 128719; 7.
DR FunCoup; Q8IZF2; 68.
DR IntAct; Q8IZF2; 8.
DR STRING; 9606.ENSP00000283296; -.
DR ChEMBL; CHEMBL4523888; -.
DR MEROPS; P02.019; -.
DR GlyConnect; Q8IZF2; 28 N-Linked glycans (14 sites).
DR GlyCosmos; Q8IZF2; 27 sites, 68 glycans.
DR GlyGen; Q8IZF2; 28 sites, 62 N-linked glycans (16 sites), 6 O-linked glycans (2 sites).
DR iPTMnet; Q8IZF2; -.
DR PhosphoSitePlus; Q8IZF2; -.
DR BioMuta; ADGRF5; -.
DR DMDM; 229462973; -.
DR jPOST; Q8IZF2; -.
DR MassIVE; Q8IZF2; -.
DR PaxDb; 9606-ENSP00000283296; -.
DR PeptideAtlas; Q8IZF2; -.
DR ProteomicsDB; 71338; -. [Q8IZF2-1]
DR ProteomicsDB; 71339; -. [Q8IZF2-2]
DR ProteomicsDB; 71340; -. [Q8IZF2-3]
DR Antibodypedia; 16896; 257 antibodies from 31 providers.
DR DNASU; 221395; -.
DR Ensembl; ENST00000265417.7; ENSP00000265417.6; ENSG00000069122.20. [Q8IZF2-1]
DR Ensembl; ENST00000283296.12; ENSP00000283296.7; ENSG00000069122.20. [Q8IZF2-1]
DR Ensembl; ENST00000888957.1; ENSP00000559016.1; ENSG00000069122.20. [Q8IZF2-1]
DR Ensembl; ENST00000888963.1; ENSP00000559022.1; ENSG00000069122.20. [Q8IZF2-1]
DR GeneID; 221395; -.
DR KEGG; hsa:221395; -.
DR MANE-Select; ENST00000283296.12; ENSP00000283296.7; NM_001098518.2; NP_001091988.1.
DR UCSC; uc003oyo.5; human. [Q8IZF2-1]
DR AGR; HGNC:19030; -.
DR ClinPGx; PA134886165; -.
DR CTD; 221395; -.
DR DisGeNET; 221395; -.
DR GeneCards; ADGRF5; -.
DR HGNC; HGNC:19030; ADGRF5.
DR HPA; ENSG00000069122; Tissue enhanced (lung).
DR MIM; 620874; gene.
DR OpenTargets; ENSG00000069122; -.
DR VEuPathDB; HostDB:ENSG00000069122; -.
DR eggNOG; KOG4193; Eukaryota.
DR GeneTree; ENSGT00940000154603; -.
DR HOGENOM; CLU_002753_3_5_1; -.
DR InParanoid; Q8IZF2; -.
DR OMA; AAESCTC; -.
DR OrthoDB; 10040049at2759; -.
DR PAN-GO; Q8IZF2; 6 GO annotations based on evolutionary models.
DR PhylomeDB; Q8IZF2; -.
DR PathwayCommons; Q8IZF2; -.
DR Reactome; R-HSA-5683826; Surfactant metabolism.
DR SignaLink; Q8IZF2; -.
DR Agora; ENSG00000069122; -.
DR BioGRID-ORCS; 221395; 16 hits in 1149 CRISPR screens.
DR ChiTaRS; ADGRF5; human.
DR GeneWiki; GPR116; -.
DR GenomeRNAi; 221395; -.
DR Pharos; Q8IZF2; Tbio.
DR PRO; PR:Q8IZF2; -.
DR Proteomes; UP000005640; Chromosome 6.
DR RNAct; Q8IZF2; protein.
DR Bgee; ENSG00000069122; Expressed in lower lobe of lung and 196 other cell types or tissues.
DR GO; GO:0009986; C:cell surface; IDA:MGI.
DR GO; GO:0031410; C:cytoplasmic vesicle; IDA:MGI.
DR GO; GO:0016020; C:membrane; TAS:GDB.
DR GO; GO:0005886; C:plasma membrane; EXP:UniProtKB.
DR GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR GO; GO:0006112; P:energy reserve metabolic process; IBA:GO_Central.
DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:GDB.
DR GO; GO:0042593; P:glucose homeostasis; IBA:GO_Central.
DR GO; GO:0043129; P:surfactant homeostasis; IBA:GO_Central.
DR CDD; cd15254; 7tmB2_GPR116_Ig-Hepta; 1.
DR FunFam; 1.20.1070.10:FF:000058; Adhesion G protein-coupled receptor F5; 1.
DR FunFam; 2.60.220.50:FF:000021; Adhesion G protein-coupled receptor F5; 1.
DR FunFam; 2.60.40.10:FF:002239; Adhesion G protein-coupled receptor F5; 1.
DR Gene3D; 2.60.220.50; -; 1.
DR Gene3D; 2.60.40.10; Immunoglobulins; 2.
DR Gene3D; 1.20.1070.10; Rhodopsin 7-helix transmembrane proteins; 1.
DR Gene3D; 3.30.70.960; SEA domain; 1.
DR InterPro; IPR057400; ADGRF3/5_N.
DR InterPro; IPR051587; Adhesion_GPCR.
DR InterPro; IPR057244; GAIN_B.
DR InterPro; IPR046338; GAIN_dom_sf.
DR InterPro; IPR017981; GPCR_2-like_7TM.
DR InterPro; IPR008078; GPCR_2_Ig-hepta-like_rcpt.
DR InterPro; IPR000832; GPCR_2_secretin-like.
DR InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR InterPro; IPR000203; GPS.
DR InterPro; IPR007110; Ig-like_dom.
DR InterPro; IPR036179; Ig-like_dom_sf.
DR InterPro; IPR013783; Ig-like_fold.
DR InterPro; IPR003599; Ig_sub.
DR InterPro; IPR003598; Ig_sub2.
DR InterPro; IPR000082; SEA_dom.
DR InterPro; IPR036364; SEA_dom_sf.
DR PANTHER; PTHR45813:SF4; ADHESION G PROTEIN-COUPLED RECEPTOR F5; 1.
DR PANTHER; PTHR45813; IG-LIKE DOMAIN-CONTAINING PROTEIN; 1.
DR Pfam; PF00002; 7tm_2; 1.
DR Pfam; PF25387; ADGRF3_N; 1.
DR Pfam; PF01825; GPS; 1.
DR Pfam; PF13927; Ig_3; 1.
DR Pfam; PF01390; SEA; 1.
DR PRINTS; PR00249; GPCRSECRETIN.
DR PRINTS; PR01695; IGHEPTARCPTR.
DR SMART; SM00303; GPS; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00408; IGc2; 2.
DR SUPFAM; SSF48726; Immunoglobulin; 2.
DR SUPFAM; SSF82671; SEA domain; 1.
DR PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
DR PROSITE; PS50221; GAIN_B; 1.
DR PROSITE; PS50835; IG_LIKE; 3.
DR PROSITE; PS50024; SEA; 1.
PE 1: Evidence at protein level;
KW Alternative splicing; Cell membrane; Disulfide bond;
KW G protein-coupled receptor; Glycoprotein; Immunoglobulin domain; Membrane;
KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome;
KW Repeat; Signal; Transducer; Transmembrane; Transmembrane helix.
FT SIGNAL 1..21
FT /evidence="ECO:0000255"
FT CHAIN 22..1346
FT /note="Adhesion G protein-coupled receptor F5"
FT /id="PRO_0000012896"
FT TOPO_DOM 22..1006
FT /note="Extracellular"
FT /evidence="ECO:0000305"
FT TRANSMEM 1007..1027
FT /note="Helical; Name=1"
FT /evidence="ECO:0000255"
FT TOPO_DOM 1028..1053
FT /note="Cytoplasmic"
FT /evidence="ECO:0000305"
FT TRANSMEM 1054..1074
FT /note="Helical; Name=2"
FT /evidence="ECO:0000255"
FT TOPO_DOM 1075..1090
FT /note="Extracellular"
FT /evidence="ECO:0000305"
FT TRANSMEM 1091..1111
FT /note="Helical; Name=3"
FT /evidence="ECO:0000255"
FT TOPO_DOM 1112..1128
FT /note="Cytoplasmic"
FT /evidence="ECO:0000305"
FT TRANSMEM 1129..1149
FT /note="Helical; Name=4"
FT /evidence="ECO:0000255"
FT TOPO_DOM 1150..1173
FT /note="Extracellular"
FT /evidence="ECO:0000305"
FT TRANSMEM 1174..1194
FT /note="Helical; Name=5"
FT /evidence="ECO:0000255"
FT TOPO_DOM 1195..1220
FT /note="Cytoplasmic"
FT /evidence="ECO:0000305"
FT TRANSMEM 1221..1241
FT /note="Helical; Name=6"
FT /evidence="ECO:0000255"
FT TOPO_DOM 1242..1244
FT /note="Extracellular"
FT /evidence="ECO:0000305"
FT TRANSMEM 1245..1265
FT /note="Helical; Name=7"
FT /evidence="ECO:0000255"
FT TOPO_DOM 1266..1346
FT /note="Cytoplasmic"
FT /evidence="ECO:0000305"
FT DOMAIN 166..273
FT /note="SEA"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00188"
FT DOMAIN 267..368
FT /note="Ig-like 1"
FT DOMAIN 369..466
FT /note="Ig-like 2"
FT DOMAIN 471..561
FT /note="Ig-like 3"
FT DOMAIN 842..1003
FT /note="GAIN-B"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00098"
FT REGION 954..1003
FT /note="GPS"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00098"
FT REGION 991..1006
FT /note="Tethered agonist"
FT /evidence="ECO:0000269|PubMed:28570277,
FT ECO:0000269|PubMed:36073784"
FT REGION 1327..1346
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 1329..1346
FT /note="Low complexity"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT SITE 51..52
FT /note="Cleavage; by furin"
FT /evidence="ECO:0000250|UniProtKB:Q9WVT0"
FT SITE 226..227
FT /note="Cleavage"
FT /evidence="ECO:0000250|UniProtKB:Q9WVT0"
FT SITE 990..991
FT /note="Cleavage; by autolysis"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00098,
FT ECO:0000305|PubMed:36073784"
FT MOD_RES 1300
FT /note="Phosphothreonine"
FT /evidence="ECO:0000250|UniProtKB:G5E8Q8"
FT MOD_RES 1307
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:G5E8Q8"
FT CARBOHYD 73
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 94
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 106
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 188
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 256
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000269|PubMed:16335952"
FT CARBOHYD 272
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 301
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 315
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000269|PubMed:16335952"
FT CARBOHYD 328
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 398
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 472
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 487
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 505
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 540
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 627
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 649
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 666
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 820
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 931
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 963
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 982
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT DISULFID 293..350
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT DISULFID 391..449
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT DISULFID 492..545
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT DISULFID 954..985
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00098"
FT DISULFID 973..987
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00098"
FT VAR_SEQ 272..414
FT /note="NESNFFVTPEIIFEGDTVSLVCEKEVLSSNVSWRYEEQQLEIQNSSRFSIYT
FT ALFNNMTSVSKLTIHNITPGDAGEYVCKLILDIFEYECKKKIDVMPIQILANEEMKVMC
FT DNNPVSLNCCSQGNVNWSKVEWKQEGKINIPG -> R (in isoform 3)"
FT /evidence="ECO:0000303|PubMed:17974005"
FT /id="VSP_039130"
FT VAR_SEQ 1273..1292
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:12435584"
FT /id="VSP_010837"
FT VAR_SEQ 1322..1346
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:12435584"
FT /id="VSP_010838"
FT VARIANT 604
FT /note="T -> M (in dbSNP:rs586024)"
FT /evidence="ECO:0000269|PubMed:10048485,
FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17974005,
FT ECO:0000269|Ref.2"
FT /id="VAR_025326"
FT VARIANT 801
FT /note="V -> I (in dbSNP:rs9395218)"
FT /evidence="ECO:0000269|PubMed:17974005"
FT /id="VAR_055291"
FT VARIANT 856
FT /note="M -> T (in dbSNP:rs547499)"
FT /evidence="ECO:0000269|PubMed:10048485,
FT ECO:0000269|PubMed:15489334"
FT /id="VAR_024477"
FT MUTAGEN 991..996
FT /note="Missing: No effect on activation by exogenous
FT ligands, nor on subcellular location. Loss of activation by
FT exogenous ligands; when associated with 1240-I--S-1243.
FT Increased activation by exogenous agonists; when associated
FT with K-l009 or with T-1252 or A-1256."
FT /evidence="ECO:0000269|PubMed:36073784"
FT MUTAGEN 1009
FT /note="G->K: No effect on activation by exogenous agonist.
FT Increased activation by exogenous agonist; when associated
FT with 991-T--L-996 del."
FT /evidence="ECO:0000269|PubMed:36073784"
FT MUTAGEN 1075..1077
FT /note="QDN->HDG: No effect on activation by exogenous
FT agonist."
FT /evidence="ECO:0000269|PubMed:36073784"
FT MUTAGEN 1080..1083
FT /note="ILCK->PLNE: No effect on activation by exogenous
FT agonist."
FT /evidence="ECO:0000269|PubMed:36073784"
FT MUTAGEN 1153
FT /note="R->Q: No effect on activation by exogenous agonist;
FT when associated with M-1157 and A-1161."
FT /evidence="ECO:0000269|PubMed:36073784"
FT MUTAGEN 1157
FT /note="T->M: No effect on activation by exogenous agonist;
FT when associated with Q-1153 and A-1161."
FT /evidence="ECO:0000269|PubMed:36073784"
FT MUTAGEN 1161
FT /note="V->A: No effect on activation by exogenous agonist;
FT when associated with Q-1153 and M-1157."
FT /evidence="ECO:0000269|PubMed:36073784"
FT MUTAGEN 1240..1243
FT /note="FPGT->IQGS: Loss of activation by exogenous ligand;
FT when associated with 991-T--L-996 del."
FT /evidence="ECO:0000269|PubMed:36073784"
FT MUTAGEN 1252
FT /note="A->T: Increased activation by exogenous agonists;
FT when associated with 991-T--L-996 del."
FT /evidence="ECO:0000269|PubMed:36073784"
FT MUTAGEN 1256
FT /note="V->A: Increased activation by exogenous agonists;
FT when associated with 991-T--L-996 del."
FT /evidence="ECO:0000269|PubMed:36073784"
FT CONFLICT 272
FT /note="Missing (in Ref. 1; AAN46672)"
FT /evidence="ECO:0000305"
FT CONFLICT 573
FT /note="V -> I (in Ref. 7; CAB43394)"
FT /evidence="ECO:0000305"
FT CONFLICT 1075
FT /note="Q -> R (in Ref. 5; AL832125)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 1346 AA; 149457 MW; 72A9D02B08218A60 CRC64;
MKSPRRTTLC LMFIVIYSSK AALNWNYEST IHPLSLHEHE PAGEEALRQK RAVATKSPTA
EEYTVNIEIS FENASFLDPI KAYLNSLSFP IHGNNTDQIT DILSINVTTV CRPAGNEIWC
SCETGYGWPR ERCLHNLICQ ERDVFLPGHH CSCLKELPPN GPFCLLQEDV TLNMRVRLNV
GFQEDLMNTS SALYRSYKTD LETAFRKGYG ILPGFKGVTV TGFKSGSVVV TYEVKTTPPS
LELIHKANEQ VVQSLNQTYK MDYNSFQAVT INESNFFVTP EIIFEGDTVS LVCEKEVLSS
NVSWRYEEQQ LEIQNSSRFS IYTALFNNMT SVSKLTIHNI TPGDAGEYVC KLILDIFEYE
CKKKIDVMPI QILANEEMKV MCDNNPVSLN CCSQGNVNWS KVEWKQEGKI NIPGTPETDI
DSSCSRYTLK ADGTQCPSGS SGTTVIYTCE FISAYGARGS ANIKVTFISV ANLTITPDPI
SVSEGQNFSI KCISDVSNYD EVYWNTSAGI KIYQRFYTTR RYLDGAESVL TVKTSTREWN
GTYHCIFRYK NSYSIATKDV IVHPLPLKLN IMVDPLEATV SCSGSHHIKC CIEEDGDYKV
TFHTGSSSLP AAKEVNKKQV CYKHNFNASS VSWCSKTVDV CCHFTNAANN SVWSPSMKLN
LVPGENITCQ DPVIGVGEPG KVIQKLCRFS NVPSSPESPI GGTITYKCVG SQWEEKRNDC
ISAPINSLLQ MAKALIKSPS QDEMLPTYLK DLSISIDKAE HEISSSPGSL GAIINILDLL
STVPTQVNSE MMTHVLSTVN VILGKPVLNT WKVLQQQWTN QSSQLLHSVE RFSQALQSGD
SPPLSFSQTN VQMSSMVIKS SHPETYQQRF VFPYFDLWGN VVIDKSYLEN LQSDSSIVTM
AFPTLQAILA QDIQENNFAE SLVMTTTVSH NTTMPFRISM TFKNNSPSGG ETKCVFWNFR
LANNTGGWDS SGCYVEEGDG DNVTCICDHL TSFSILMSPD SPDPSSLLGI LLDIISYVGV
GFSILSLAAC LVVEAVVWKS VTKNRTSYMR HTCIVNIAAS LLVANTWFIV VAAIQDNRYI
LCKTACVAAT FFIHFFYLSV FFWMLTLGLM LFYRLVFILH ETSRSTQKAI AFCLGYGCPL
AISVITLGAT QPREVYTRKN VCWLNWEDTK ALLAFAIPAL IIVVVNITIT IVVITKILRP
SIGDKPCKQE KSSLFQISKS IGVLTPLLGL TWGFGLTTVF PGTNLVFHII FAILNVFQGL
FILLFGCLWD LKVQEALLNK FSLSRWSSQH SKSTSLGSST PVFSMSSPIS RRFNNLFGKT
GTYNVSTPEA TSSSLENSSS ASSLLN
//